TLSA — Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: GB
- Exchange: NASDAQ
- Employees: 9
- Website: https://www.tizianalifesciences.com
Latest SEC filings for TLSA
- 6-K — 2026-10-21
- 6-K — 2026-10-16
- 6-K — 2026-10-16
- 6-K — 2026-09-30
- 6-K — 2026-09-28
- 6-K — 2026-09-21
- 6-K — 2026-09-17
- 6-K — 2026-08-24
- 6-K — 2026-08-06
- 6-K — 2026-08-04
Latest TLSA news
- — Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
- — Tiziana doses first three patients in ALS trial of nasal antibody foralumab (proactiveinvestors.com)
Educational tool only — not investment advice.